The Parkinson's disease VPS35[D620N] mutation enhances LRRK2 mediated Rab protein phosphorylation in mouse and human by Mir, Rafeeq et al.
                                                              
University of Dundee
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2 mediated Rab
protein phosphorylation in mouse and human
Mir, Rafeeq; Tonelli, Francesca; Lis, Pawel; Macartney, Thomas; Polinski, Nicole K.;
Martinez, Terina N.; Chou, Meng-Yun ; Howden, Andrew; König, Theresa ; Hotzy, Christoph ;
Milenkovic, Ivan ; Brücke, Thomas ; Zimprich, Alexander ; Sammler, Esther; Alessi, Dario
Published in:
Biochemical Journal
DOI:
10.1042/BCJ20180248
Publication date:
2018
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Mir, R., Tonelli, F., Lis, P., Macartney, T., Polinski, N. K., Martinez, T. N., ... Alessi, D. (2018). The Parkinson's
disease VPS35[D620N] mutation enhances LRRK2 mediated Rab protein phosphorylation in mouse and
human. Biochemical Journal, 475(11), 1861-1883. https://doi.org/10.1042/BCJ20180248
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
 The Parkinson’s disease VPS35[D620N] mutation enhances LRRK2 mediated Rab protein 
phosphorylation in mouse and human  
Rafeeq Mir1#, Francesca Tonelli1#, Pawel Lis1, Thomas Macartney1, Nicole K Polinski2, Terina 
N. Martinez2, Meng-Yun Chou3, Andrew J.M. Howden4, Theresa König5, Christoph Hotzy5,
Ivan Milenkovic5, Thomas Brücke6, Alexander Zimprich6, Esther Sammler1,7*, Dario R. Alessi1* 
1. MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University
of Dundee, Dundee, United Kingdom DD1 5EH, United Kingdom.
2. The Michael J. Fox Foundation for Parkinson’s Research, Grand Central Station, P.O. Box
4777, New York, NY 10163, USA.
3. Abcam, 863 Mitten Rd, Burlingame, CA 94010, USA.
4. Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee,
Dundee, United Kingdom.
5. Department of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090
, Austria.
6. Verein zur Förderung der wissenschaftlichen Forschung im, Wilhelminenspital (FWFW),
Montleartstrasse 37, 1160 Wien, Austria.
 Department of Neurology, School of Medicine, Dundee, Ninewells Hospital, Ninewells
Drive, Dundee DD1 9SY, United Kingdom.
# These authors made an equal contribution to this study 
* Correspondence to Esther Sammler (e.m.sammler@dundee.ac.uk) or Dario Alessi
(d.r.alessi@dundee.ac.uk) 
Running title “VPS35 lies upstream of LRRK2” 
Key Words: Rab proteins, Vesicle trafficking, GTPase and Phosphorylation 
ACCEPTED M
ANUSCRIPT 
10.1042/BCJ20180248
. Please cite using the DOI 10.1042/BCJ20180248http://dx.doi.org/up-to-date version is available at 
encouraged to use the Version of Record that, when published, will replace this version. The most 
 this is an Accepted Manuscript, not the final Version of Record. You are:Biochemical Journal
). http://www.portlandpresspublishing.com/content/open-access-policy#Archiving
Archiving Policy of Portland Press (
which the article is published. Archiving of non-open access articles is permitted in accordance with the 
Use of open access articles is permitted based on the terms of the specific Creative Commons Licence under
 2 
Abstract 
Missense mutations in the LRRK2 and VPS35 genes result in autosomal dominant Parkinson’s 
disease. The VPS35 gene encodes for the cargo-binding component of the retromer complex, 
while LRRK2 modulates vesicular trafficking by phosphorylating a subgroup of Rab proteins. 
Pathogenic mutations in LRRK2 increase its kinase activity. It is not known how the only thus 
far described pathogenic VPS35 mutation, [D620N] exerts its effects. We reveal that the 
VPS35[D620N] knock-in mutation, strikingly elevates LRRK2 mediated phosphorylation of 
Rab8A, Rab10 and Rab12 in mouse embryonic fibroblasts. The VPS35[D620N] mutation also 
increases Rab10 phosphorylation in mouse tissues (lung, kidney, spleen and brain). Furthermore, 
LRRK2 mediated Rab10 phosphorylation is increased in neutrophils as well as monocytes 
isolated from three Parkinson’s patients with a heterozygous VPS35[D620N] mutation compared 
to healthy donors and idiopathic Parkinson’s patients. LRRK2 mediated Rab10 phosphorylation 
is significantly suppressed by knock-out or knock-down of VPS35 in wild type, 
LRRK2[R1441C] or VPS35[D620N] cells. Finally, VPS35[D620N] mutation promotes Rab10 
phosphorylation more potently than LRRK2 pathogenic mutations. Available data suggest that 
Parkinson’s patients with VPS35[D620N] develop the disease at a younger age than those with 
LRRK2 mutations. Our observations indicate that VPS35 controls LRRK2 activity and that the 
VPS35[D620N] mutation results in a gain of function, potentially causing Parkinson’s disease 
through hyperactivation of the LRRK2 kinase. Our findings suggest that it may be possible to 
elaborate compounds that target the retromer complex to suppress LRRK2 activity. Moreover, 
patients with VPS35[D620N] associated Parkinson’s might benefit from LRRK2 inhibitor 
treatment that have entered clinical trials in humans. 
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Introduction 
Parkinson’s disease (PD) is a common neurodegenerative condition with numbers expected to 
rise [1]. There is currently no test for diagnosis, cure or disease modifying therapies available. 
Although most PD cases are idiopathic, studying the disease mechanisms of the rarer genetic PD 
forms is expected to advance our knowledge in the aetiology of idiopathic disease and help 
identify targets for the development of biomarker and novel treatments. Mutations in at least 18 
genes have been linked to heritable forms of PD and may be indistinguishable from idiopathic 
disease[2, 3]. That mutations in LRRK2 (Leucine Rich Repeat protein kinase-2) result in PD was 
first described in 2004 [4, 5] and are one of the most common genetic causes for PD. For 
example, the most frequent LRRK2 mutation (G2019S) is found in 4% of familial and up to 1-
2% of sporadic PD patients worldwide [3, 6] and with much higher frequency, for example, in 
Ashkenazi Jews (28% of familial and 10% of sporadic PD) and North African Berbers (36% of 
familial and 42% of sporadic cases) [4, 5, 7]. LRRK2 is a large multi-domain protein kinase 
consisting of a ROC-type GTPase domain in addition to a serine/threonine protein kinase domain 
[8]. The best characterised pathogenic mutations lie within the ROC domain (R1441C/G, 
Y1699C) and the kinase domain (G2019S) [9]. The G2019S mutation directly increases kinase 
activity of recombinant LRRK2 [9], while the R1441G/C and Y1699C mutations do so indirectly 
by promoting the recruitment of LRRK2 to the Rab29 protein located at the Golgi, leading to 
LRRK2 activation through an as yet unknown mechanism [10-12].  
 
Recent work has identified a subgroup of up to 14 endogenous Rab GTPase proteins 
(Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29, Rab35, and Rab43) as direct 
substrates for LRRK2 [13, 14]. Rab proteins orchestrate membrane and vesicle trafficking [15, 
16]. The LRRK2 phosphorylation site (Thr72 for Rab8A, Thr73 for Rab10, and Ser106 for 
Rab12), for Rab proteins lies at the centre of the effector-binding, switch-II motif and is likely to 
exert its biological effect by altering ability of Rab proteins to interact with cognate effectors [13, 
14, 17]. Recent work identified the RILPL1 and RILPL2 proteins, implicated in regulating 
ciliary membrane content [18], to specifically bind Rab8 and Rab10 via an RH2 domain, once 
phosphorylated by LRRK2 [14]. Phosphorylation of Rab8 and Rab10 by LRRK2 also prevent 
interactions with the effectors such as Rabin-8 (a GDP/GTP exchange factor) and GDI (GDP 
Dissociation Inhibitor) [13, 17]. Our working model is that elevated LRRK2 activity contributes 
to the development of PD by inducing hyperphosphorylation of Rab proteins. This is supported 
by the finding that all pathogenic LRRK2 mutations significantly stimulate Rab protein 
phosphorylation [13, 14, 19, 20]. Other studies have also linked disruption of Rab biology to PD 
and other forms of neurodegeneration (reviewed in [21]). For example, variations around Rab29 
as well as disease causing mutations in Rab39B and at least 3 other membrane trafficking 
machinery components (VPS35, VPS13C, DNAJC6) are genetically associated with PD [2, 3, 
22]. PINK1 also indirectly controls the phosphorylation of certain Rab GTPases including 
Rab8A, at a site distinct to LRRK2 (Ser111 on Rab8A) [23]. Furthermore, various Rab proteins, 
attenuate cytotoxicity linked to aggregated α-synuclein, a factor that is associated with PD and 
other neurodegenerative diseases [24]. 
 
There is also mounting evidence that disruption of selective transport between membrane-bound 
organelles and the plasma membrane is a feature of PD [22, 25]. A key component regulating 
selective transport is the retromer complex, which is made up of 3 proteins (VPS35, VPS29 and 
VPS26). This operates to package specific endosomal cargoes into vesicles and tubules, and 
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deliver these to either the trans-Golgi network or to the plasma membrane [26]. In 2011, two 
groups reported that heterozygous changes in the gene encoding for the VPS35 cargo binding 
component of the retromer complex are associated with late onset PD [27, 28]. Subsequent 
reports have revealed that VPS35 associated PD is overall rare with an estimated frequency of 
0.4% of all PD cases and that - with over 15000 individuals worldwide studied – the 
VPS35[D620N] is the only clearly pathogenic mutation characterised to date (reviewed in [29, 
30]). Interestingly, the structure of a VPS35 sub-complex [31], shows that the VPS35[D620N] 
mutation is located at the surface of the convex face of an α-helical solenoid domain (Fig 1), 
suggesting that the D620N mutation may impact interaction with an as yet unknown effector.  
 
Previous work has linked LRRK2 and VPS35. This includes studies undertaken in mouse 
neurons as well as Drosophila, that concluded that VPS35 and LRRK2 might operate in a 
common pathway regulating protein endolysosomal and Golgi apparatus sorting [32]. Another 
study found that overexpression of VPS35 or VPS26 ameliorated the pathogenic effects on the 
eye, as well as locomotor deficits and reduced lifespan observed in LRRK2 mutant flies [33]. 
Moreover, Drosophila VPS35 and LRRK2 were shown to affect the same set of synaptic vesicle 
processes including dopaminergic synaptic release [34]. To further investigate the interplay 
between VPS35 and LRRK2, we explored whether genetic manipulations of VPS35 – knock-in 
of the VPS35[D620N] mutation or knock-down and knock-out of VPS35 - impacted on LRRK2 
mediated Rab protein phosphorylation. In mouse embryonic fibroblasts (MEFs), mouse tissues 
(lung, kidney, spleen and brain) as well as patient-derived peripheral blood neutrophils and 
monocytes, the VPS35[D620N] mutation resulted in a marked elevation of LRRK2 mediated 
phosphorylation of Rab10 at Thr73. Using novel monoclonal antibodies and mass spectrometry 
approach we demonstrate that VPS35[D620N] mutation also promotes LRRK2 mediated 
phosphorylation of a number of other Rab proteins (Rab8A, Rab10 and Rab12). Moreover, 
knock-out or knockdown of VPS35 also suppressed LRRK2 mediated Rab10 phosphorylation in 
cells. Although further work is required to pinpoint the mechanism by which VPS35 regulates 
LRRK2, our studies establish that VPS35 plays a major role in controlling LRRK2 protein 
kinase activity. Furthermore, our findings support the model that VPS35[D620N] mutation 
results in a gain of function and is an upstream regulator of the LRRK2 kinase pathway.  
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Materials and Methods 
 
Reagents 
MLi-2 [35, 36] and GSK2578215A [37] and LRRK2 inhibitors were synthesized by Natalia 
Shpiro (University of Dundee). The PF-06447475 LRRK2 inhibitor [38] was purchased from 
Tocris (#5716), diisopropylfluorophosphate (DIFP) was from Sigma (# D0879) and 
phenylmethane sulfonyl fluoride (PMSF) was from Sigma (# 78830). All peptide antigens were 
synthesised by “peptides and elephants” (http://www.peptides.de/) and HPLC purified and stored 
in aliquots in sealed glass ampules in argon to avoid oxidation. 
 
Generation of Rabbit monoclonal Rab8A (MJF-22) and Phospho-Ser106 Rab12 (MJF-25) 
antibodies.  
Rabbit immunization and rabbit antibody generation was performed by Abcam Inc. (Burlingame, 
CA). For the phospho-Ser106 Rab12 antibody, eight New Zealand White rabbits were 
immunized with target immunogens described in Table 1 using a standard protocol of five 
injections and two bleedings for each rabbit. Three subcutaneous injections were performed 
using the KLH-immunogens, followed by two subcutaneous injections using the ovalbumin-
immunogens. At the time of each injection, an immunogen aliquot was thawed and combined 
with Complete Freund’s Adjuvant (initial immunization), or with incomplete Freund’s Adjuvant 
(for the subsequent injections). For the total Rab8A antibody (MJF-22), six New Zealand White 
rabbits were immunized with a protocol of 6 injections and 3 bleedings for each rabbit. The first 
4 injections were undertaken with the full length human Rab8A protein and the final two 
injections were undertaken with a C-terminal human Rab8A peptide shown in Table 1 
conjugated to KLH.  rabbits producing the best antibody was chosen for monoclonal antibody 
generation and was intravenously boosted with immunogen 4 days before splenectomy (for the 
MJFF-Rab8A programme this was undertaken using C-terminal peptide shown in Table 1). 
Hybridoma fusion was performed according to established protocol with minor modifications 
[39]. Briefly, splenocytes were harvested from the immunized rabbit and fused with rabbit 
plasmacytoma cells 240E-W2 [40] using PEG4000 (Sigma Chemical, St. Louis, MO) and 
selected by HAT (hypoxanthine, aminopterin, and thymidine). At the end of the selection, 
hybridoma clones growing in the original 96-well plates were transferred to 24-well plates with a 
medium change. Hybridoma supernatants were collected and screened for antigen binding by 
ELISA and western blot. Hybridomas that were specific in both assays were subcloned, 
expanded and recombinant antibody prepared. For the Rab8A programme antibody MJFF-22-74-
3 was selected. For the phospho-Ser106 Rab12 programme antibody MJFF-25-9-1 was selected. 
All data shown in this study were undertaken with recombinant antibody diluted in 5% BSA 
(Bovine Serum Albumin) in TBS-T. The MJFF-Rab8A and MJFF-pRab12 rabbit monoclonal 
antibodies will be available commercially from Abcam (www.abcam.com) in 2018. To validate 
the Rab12-pS106 (MJF-25-9-1) antibody, cross-reactivity was assessed using a panel of 
overexpressed Rab proteins as described previously [20], as well as using lysates of wild-type 
and Rab12 knock-out A549 cell lines described below. 
 
Other Antibodies 
Mouse anti-LRRK2 C-terminus antibody was from Antibodies Incorporated (#75-253) and used 
at 1 µg/ml final concentration. Rabbit monoclonal antibodies for total LRRK2 (UDD3) and 
pS935-LRRK2 (UDD2) were purified at the University of Dundee as described previously [41] 
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and were used at 1 µg/ml final concentration. The recombinant MJFF-pRab10 (Thr73) MJF-21-
108-10 rabbit monoclonal antibody was recently described [20] and is now available from 
Abcam (#ab230261). The recombinant MJFF-pRab8 (Thr72) MJF-20-55-4 rabbit monoclonal 
antibody that detects multiple LRRK2 phosphorylated Rab proteins was also recently described 
[20]. All recombinant antibodies were used at 1 µg/ml final concentration. The MJFF-total 
Rab10 mouse antibody generated by nanoTools (www.nanotools.de) [20] was used at 2 µg/ml 
final concentration. Rabbit monoclonal antibody for LRRK2 Phospho-S1292 (#ab203181), 
VPS35 (#ab157220) and VPS26 (#ab181352) were from Abcam and were all used at 1:1000 
dilution. Rabbit polyclonal Rab12 antibody was from Proteintech (18843-1-AP) and was used at 
1:500 dilution. Sheep polyclonal Rab12 has been described earlier (Lis et al. 2018) and was used 
at 1 µg/ml. Anti-α-tubulin (#5174) antibody was from Cell Signaling Technologies and used at 
1:2000 dilution. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from 
Santa Cruz Biotechnology (#sc-32233) and used at 50 ng/ml final concentration. Horseradish 
peroxidase-conjugated anti-mouse (#31450) and -rabbit (#31460) secondary antibodies were 
from Thermo Fisher Scientific and used at 1:2500 dilution. Goat anti-mouse IRDye 800CW 
(#926-32210) and IRDye 680LT (#926-68020) and goat anti-rabbit IRDye 800CW (#926-32211) 
secondary antibodies were from LI-COR and used at 1:10,000 dilution. LI-COR Quick Western 
Kit (IRDye® 680RD, # 926-68100) was used at 1:1000 dilution.  
 
Mice  
Mice were maintained under specific pathogen-free conditions at the University of Dundee 
(UK). All animal studies were ethically reviewed and carried out in accordance with Animals 
(Scientific Procedures) Act 1986 and regulations set by the University of Dundee and the U.K. 
Home Office. Animal studies and breeding were approved by the University of Dundee ethical 
committee and performed under a U.K. Home Office project license. Mice were multiply housed 
at an ambient temperature (20–24°C) and humidity (45–55%) and maintained on a 12 h light/12 
h dark cycle, with free access to food (SDS RM No. 3 autoclavable) and water. 
 
Generation of VPS35[D620N] knock-in mice 
 The Michael J. Fox Foundation for Parkinson’s Research generated the VPS35 D620N knock-in 
mice (B6(Cg)-Vps35tm1.1Mjff/J) in collaboration with Ozgene and The Jackson Laboratory. A 
floxed "mini-cDNA" was used to enable expression of the wild-type VPS35 protein prior to Cre-
mediated recombination. The floxed "mini-cDNA" (consisting of a splice acceptor, a sequence 
encoding exons 15 through 17, and a polyadenylation signal), with a FRT site flanked NEO 
cassette on the 3'end of the mini-cDNA and a third loxP site, was inserted into intron 14-15. The 
construct was electroporated into C57BL/6 derived Bruce4 embryonic stem (ES) cells. Correctly 
targeted ES cells were injected into blastocysts and the resulting chimeric animals were tested for 
germline transmission. The mice were then crossed to FLP expressing mice on the C57BL/6J 
genetic background, to remove the NEO cassette. The FLP recombinase transgene was then bred 
out from the line. The mice were then crossed to C57BL/6J (JAX stock No. 000664) at least 
once before being crossed to Cre deleter line on the B6 background (JAX stock No. 008454) to 
remove the floxed "mini-cDNA" sequence and allow expression of the D620N mutation that had 
been targeted into exon 15. The mice were then bred to remove the Cre recombinase allele 
(https://www.jax.org/strain/023409). These mice are available from The Jackson Laboratory 
(JAX stock No. 023409). 
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Genotyping of mice was performed by PCR using genomic DNA isolated from ear biopsies. For 
this purpose, Primer 1 (5’-TCATTCTGTGGTTAGTTCAGTTGAG -3’), Primer 2 (5’ –
CCTCTAACAACCAAGAGGAACC -3’) and Primer 3 (5’- ATTGCATCGCATTGTCTGAG -
3’) were used to distinguish wild type from D620N knock-in alleles. DNA sequencing was used 
to confirm the knock-in mutation and performed by DNA Sequencing & Services (MRC–PPU; 
http://www.dnaseq.co.uk) using Applied Biosystems Big-Dye version 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. 
 
For experiments shown in Figure 4, nine to ten-week-old age littermate matched wild-type and 
VPS35[D620] knock-in mice were injected subcutaneously either with vehicle [40% (w/v) (2-
hydroxypropyl)-β-cyclodextrin (Sigma–Aldrich)] or MLi-2 dissolved in vehicle at 30 mg/kg 
dose. Mice were killed by cervical dislocation 60 min after treatment and tissues rapidly isolated 
and snap-frozen in liquid nitrogen. No specific randomization method or blinding was applied to 
experiments. 
 
Generation of Mouse Embryonic Fibroblasts 
Wild-type, heterozygous and homozygous VPS35[D620N] knock-in MEFs were isolated from 
littermate-matched mouse embryos at day E12.5 resulting from crosses between heterozygous 
VPS35[D620N]/wild type mice as described previously [42]. Littermate-matched wild type and 
LRRK2[R1441C] [14] and littermate-matched wild type and LRRK2[G2019S] [20] knock-in 
MEFs were described recently. Littermate-matched wild type and homozygous LRRK2 knock-
out MEFs were isolated from LRRK2 knock-out mice [43] as described previously [41]. All 
knock-in and knock-out cell lines were verified by PCR. 
 
Generation of CRISPR/Cas9 knockout of VPS35 in A549 Cells 
To generate VPS35 knockout A549 cells, a modified Cas9 nickase system was used. Guides 
were chosen following careful transcript analysis using both NCBI and Ensembl and identified 
using the Sanger Centre CRISPR finder tool (http://www.sanger.ac.uk/htgt/wge/find_crisprs). 
Optimal sgRNA pairs were identified with a low combined offtargeting score (VPS35 KO
sgRNA1: GCCTGGTAAGAATGGAGATGT (DU57741); sgRNA2: 
GCTGGACCTTCACAGCCTGTA (DU57754)). Complementary oligos with BbsIcompatible 
overhangs were designed for each and the dsDNA guide inserts ligated into BbsIdigested target 
vectors; the antisense guides (sgRNA2) were cloned onto the spCas9 D10Aexpressing pX335 
vector (Addgene plasmid no. 42335) and the sense guides (sgRNA1) into the puromycin
selectable pBABED P U6 plasmid (Dundeemodified version of the original Cell Biolabs 
pBABE plasmid). A549 cells at ~80% confluency were cotransfected with DU57741 and 
DU57754 plasmids using Lipofectamine LTX according to the manufacturer's instructions, with 
a final amount of 6 μl Lipofectamine LTX and 3 μg of DNA per well in a 6 well plate. 24 hours 
after transfection, medium was replaced with fresh medium supplemented with 2 μg/ml of 
puromycin. After 24 h of puromycin selection, medium was replaced again with fresh medium 
without puromycin and the cells were left to recover for 48 h before performing singlecell 
sorting. Wild-type A549 cells were also single-cell sorted in parallel and three single clones were 
selected and used as controls alongside the VPS35 knockout clones. Cell sorting was performed 
using Influx cell sorter (Becton Dickinson). Single cells were placed in individual wells of a 96
well plate containing DMEM supplemented with 10% FBS, 2 mM Lglutamine, 100 units/ml 
penicillin, and 100 mg/ml streptomycin and 100 mg/ml Normocin (InvivoGen). After reaching 
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~80% confluency, individual clones were transferred into sixwell plates. After reaching ~80% 
confluency, the clones were screened for VPS35 expression by immunoblotting. 
 
siRNA-mediated knockdown of VPS35 and LRRK2 in MEFs 
Pre-designed siRNA were ordered from Dharmacon: ON-TARGETplus Mouse Vps35 (65114) 
siRNA – SMARTpool (# L-063309-01-0005), ON-TARGETplus Mouse LRRK2 siRNA-
SMARTpool (#L-049666-00-0005)and ON-TARGETplus Non-targeting Pool (# D-001810-10-
05). MEFs at 70-80% confluence were transfected with non-targeting control siRNA or VPS35 
or LRRK2 siRNA at a final concentration of 50 nM using RNAiMAX transfection reagent 
according to manufacturer’s instructions and harvested 72 hours after transfection. 
 
Cell culture, treatment and lysis 
A549 cells were grown in DMEM containing 10 % foetal calf serum, 2 mM L-glutamine, 100 
U/ml penicillin and 100 mg/ml streptomycin. MEFs were grown in DMEM containing 10% 
foetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin 
supplemented with non-essential amino acids and 1 mM sodium pyruvate. All cells were grown 
at 37C, 5% CO2 in a humidified atmosphere. All cell lines were tested regularly for mycoplasma 
contamination. Cells were treated with LRRK2 inhibitor MLi-2 at a final concentration of 100 
nM for 60 minutes. Cells were lysed in ice-cold lysis buffer containing 50 mM Tris/HCl, pH 7.4, 
1% (v/v) Triton X-100, 10% (v/v) Glycerol, 1 mM sodium orthovanadate, 50 mM NaF, 10 mM 
2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 μg/ml mycrocystin-LR (Enzo Life 
Sciences, Switzerland) and complete EDTA-free protease inhibitor cocktail (Roche). Lysates 
were clarified by centrifugation at 20,800 g at 4C for 10 minutes and supernatants were 
quantified by Bradford assay. 
 
Mouse tissue lysate preparation 
Frozen mouse tissues were rapidly defrosted in ice-cold lysis buffer [50 mM Tris–HCl, pH 7.5, 
1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 10 mM 2-
glycerophosphate, 5 mM sodium pyrophosphate, 0.1 µg/ml microcystin-LR (Enzo Life 
Sciences), 270 mM sucrose and complete EDTA-free protease inhibitor cocktail (Sigma–Aldrich 
Cat # 11836170001)] and homogenised using a POLYTRON homogenizer (KINEMATICA) on 
ice (5 s homogenisation, 10 s interval and 5 s homogenisation). Lysates were clarified by 
centrifugation at 20 800 g for 30 min at 4°C and supernatants were quantified by Bradford assay 
and used for subsequent immunoblot analysis. 
 
LRRK2 immunoprecipitation 
To assess endogenous LRRK2 S1292 phosphorylation in VPS35 wild type, D620N heterozygous 
and D620N homozygous MEFS, LRRK2 was immunoprecipitated from lysates (2 mg of protein) 
using 4 μg of anti-LRRK2 antibody UDD3 coupled to Protein A Sepharose beads. 
Immunoprecipitated LRRK2 was washed three times with lysis buffer and eluted from the beads 
with 2X NuPAGE LDS Sample Buffer. Eluted samples were used for detecting total LRRK2 and 
phospho-Ser1292 LRRK2 by immunoblotting analysis. For detecting immunoprecipitated 
LRRK2 (phospho and total), VeriBlot secondary antibody (Abcam, #ab131366) was used instead 
of normal anti-rabbit IgG secondary antibody. 
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A549 knock-out cell lines 
The A549 Rab8A knock-out cell line has been described previously [14]. The A549 Rab12 
knockout cell line was generated using the DU54555/DU54559 constructs (available at 
https://mrcppureagents.dundee.ac.uk), targeting exon 3 of Rab12. Cells at about 80% confluency 
were co-transfected in a six-well plate with the pair of constructs using Lipofectamine LTX 
reagent, with a final amount of 9 µl Lipofectamine LTX and 2.5 mg DNA per well. 24 h after 
transfection, the medium was replaced and fresh medium supplemented with puromycin (2 
mg/ml). After 24 h selection, the medium was replaced with medium without puromycin and the 
cells were left to recover for 48 h before performing single-cell sorting using an Influx cell sorter 
(Becton Dickinson). Single cells were placed in individual wells of a 96-well plate containing 
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin and 100 
mg/ml streptomycin and 100 mg/ml normocin (InvivoGen). At about 80% confluency individual 
clones were transferred into six-well plates and screened for Rab12 knock-out by western 
blotting. 
 
Rab8A immunoprecipitation to assess endogenous Rab8A phosphorylation 
To assess endogenous Rab8A phosphorylation, 1 μg of the recombinant MJF-22-74-3 antibody 
was coupled to 5 µl of Protein A Sepharose. 100 μg of cell lysate was incubated for 1 hour with 
Protein A Sepharose-antibody conjugate at 4 oC with gentle agitation. The supernatant from each 
immunoprecipiate are retained and subjected to Rab8A immunoblot analysis in comparison with 
whole cell lysate to ascertain quantitative immuno-depletion of endogenous Rab8A. 
Immunoprecipitates were washed three times with the same buffer employed to lyse cells with. 
The washed beads are incubated 10 µl of 2X NuPAGE LDS Sample Buffer, vortexed and 
centrifuged through a Spin-X column to remove beads. The eluted sample was subjected to 
immunoblot analysis with both total Rab8A antibody (10% of sample) and Rab8-pT72 antibody 
(90% of sample). LiCor Quick Western Kit (IRDye® 680RD) was used as a secondary antibody 
for this analysis. To validate the immunoprecipitation efficiency the post-IP supernatants were 
subjected to Rab8A immunoblotting. 
 
Study participants and blood sample collection 
For setting up and validating the LRRK2 activity assay in human monocytes, we recruited 
volunteers from within the School of Life Sciences at the University of Dundee who kindly 
donated blood for the present study. Specifically, the data shown in Figure 6 are derived from 
three healthy volunteers from Dundee. For the clinical part of our study (in Figure 5 & 7), blood 
was collected with ethical approval and consent to participate was granted by the respective local 
ethics committees of the University of Dundee in the United Kingdom as well as the Medical 
University of Vienna in Austria. All participants provided informed consent. 
 
Monocyte isolation, characterisation, treatments and lysis 
Monocytes were isolated from peripheral human blood by immunomagnetic negative selection 
using the EasySep Human Monocyte Isolation Kit (STEMCELL Technologies, Cat# 19359) and 
Easy 50 EasySep Magnets (STEMCELL Technologies, Cat# 18002) following the 
manufacturer’s protocol. 20 ml of whole blood were collected in K2-EDTA BD vacutainers 
(Cat# BD 367525) and transferred into a 50 ml falcon tube. Additional EDTA in phosphate-
buffered saline (PBS) to a concentration of EDTA at 1 mM was added (although this is not a 
specific requirement of the manufacturer), and tubes were gently mixed by inversion. 1 ml of 
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‘Isolation Cocktail’ from the monocyte isolation kit was added to the whole blood (i.e. 50 µl/ml 
of blood). 1 ml of resuspended RapidSpheres magnetic beads from the isolation kit were added 
to the blood sample (i.e. 50 µl/ml of blood), which was then gently mixed by inversion and 
incubated at room temperature for 5 min. The sample was then diluted to a final volume of 50 ml 
with 1 mM EDTA in PBS and then gently mixed by inversion of the tube. The falcon tube was 
next placed into the Easy 50 EasySep Magnet without lid (to avoid subsequent agitation of the 
sample) and incubated for 10 min at room temperature to remove non-monocyte blood cells. The 
supernatant containing the enriched monocyte suspension was carefully pipetted into a new 50 
ml falcon tube, avoiding to disrupt the magnetic beads attached to the sides of the falcon tube 
that is in contact with the magnet as well as the red blood cells that accumulated at the bottom of 
the tube. To further purify monocytes, another 1 ml of resuspended RapidSpheres magnetic 
beads was added to the enriched neutrophils, and the sample was gently mixed by tube inversion 
and incubated at room temperature for 5 min. The tube was then placed into the EasySep Magnet 
without lid and after 5 min incubation at room temperature, the supernatant containing highly 
purified monocytes was carefully pipetted into a new 50 ml falcon tube, taking care to collect 
only the clear fraction. To ensure complete removal of magnetic beads from the cell mixture, the 
resulting monocyte suspension was placed for a final time in the magnet (without lid) and after 
10 min incubation, the pure monocyte cell suspension was carefully pipetted into a new tube, 
ensuring that only the clear fraction was collected. The resulting isolated monocytes were 
centrifuged at 335 g for 5 min (acceleration and deceleration are both set to 5 using a Beckman 
Coulter Allegra X-15R Centrifuge) and resuspended in 10 ml RPMI 1640 media at room 
temperature by gentle pipetting. The cell suspension was divided equally into two tubes (each 
containing 5 ml), and either LRRK2 inhibitor MLi-2 (200 nM final concentration) or an 
equivalent volume of DMSO (0.1% v/v) were added to the media. After 30 minute incubation at 
room temperature, monocytes were pelleted through centrifugation at 335 g for 5 min and cell 
pellets were lysed in ice-cold lysis buffer containing 50 mM Tris–HCl, pH 7.5, 1% (v/v) Triton 
X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 10 mM 2-glycerophosphate, 5 
mM sodium pyrophosphate, 270 mM sucrose, 1 µg/ml mycrocystin-LR, 0.5 mM DIFP (Sigma, 
Cat# D0879, freshly added to lysis buffer just before lysing cells) and Complete EDTA-free 
protease inhibitor cocktail. Samples were left on ice for 15 minutes to allow for efficient lysis 
before being clarified by centrifugation at 20,800 g at 4C for 10 minutes. Supernatants were 
quantified by Bradford assay and used for immunoblotting analysis. 
 
The viability and purity of monocytes after isolation was checked by flow cytometry analysis. 
Isolated cells were incubated with 2.5 μg human FC block (BD Biosciences, Cat# 564220) in 
100 μl FACS buffer for 10 minutes at room temperature. FACS buffer comprised of Dulbecco’s 
PBS (Thermo Fisher Scientific, Cat# 14190094) + 1 % foetal bovine serum (Thermo Fisher 
Scientific, Cat# 10270106). After blocking, cells were stained with the monocyte specific cell 
surface marker CD14 using anti-human CD14 V500 (BD Biosciences, Cat# 561392, clone 
M5E2) at 1:20 dilution according to the manufacturer’s instructions. Cells were also stained with 
4',6-Diamidino-2-Phenylindole (DAPI, Thermo Fisher Scientific, Cat# D1306) at 2.5 μg/ml 
before analysis on a FACS LSR Fortessa flow cytometer with DIVA software (BD Biosciences). 
Data was analysed using FlowJo software (FlowJo, LLC).  
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Neutrophil and PBMC isolation, characterisation, treatments and lysis 
Neutrophils and PBMCs were isolated from peripheral human blood and purity and viability and 
cell lysis performed as described previously [44].  
 
Immunoblotting analysis 
Cell/tissue lysates were mixed with NuPAGE LDS Sample Buffer (Life Technologies) 
supplemented with 1% (v/v) 2-mercaptoethanol and heated at 70°C for 10 min. 10–20 μg 
samples were loaded on to NuPAGE 4-12% Bis-Tris Midi Gels (Thermo Fisher Scientific, Cat# 
WG1403) and electrophoresed at 130 V in NuPAGE MOPS SDS running buffer (Thermo Fisher 
Scientific, Cat# NP0001-02). Proteins were then transferred onto nitrocellulose membranes (GE 
Healthcare, Amersham Protran Supported 0.45 µm NC) at 100 V for 90 min on ice in transfer 
buffer [48 mM Tris–HCl and 39 mM glycine]. Transferred membranes were blocked with 5% 
(w/v) non-fat dry milk powder dissolved in TBS-T [20 mM Tris/HCl, pH 7.5, 150 mM NaCl and 
0.1% (v/v) Tween 20] at room temperature for 30 min. Membranes were then incubated with 
primary antibodies diluted in 5% BSA in TBS-T overnight at 4°C. After washing membranes in 
TBS-T, membranes were incubated at room temperature for 1 h with either HRP-labelled 
secondary antibody (Thermo Fisher Scientific #31480, #31460, #31430) diluted (1 : 2500) in 5% 
non-fat dry milk/TBS-T or with near-infrared fluorescent IRDye antibodies (LI-COR #925-
68070, #925-32211) diluted (1 : 10 000) in TBS-T (without milk or BSA). After extensive 
washing in TBS-T, the membranes were developed either using ECL [Amersham ECL Western 
Blotting Detection Reagents (GE Healthcare)] or using the LI-COR Odyssey CLx Western Blot 
imaging system and signal quantified using the Image Studio software. 
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Results 
VPS35[D620N] mutation enhances LRRK2 mediated phosphorylation of Rab10 in mouse 
embryonic fibroblasts  
To investigate whether the VPS35[D620N] pathogenic mutation [27, 28], impacts on LRRK2 
kinase activity, we obtained VPS35[D620N] knock-in mice created by The Michael J. Fox 
foundation for Parkinson’s research and made available through the Jackson laboratory 
(https://www.jax.org/strain/023409). The acquired strain had the original mini-gene removed 
using Cre recombinase, to allow for the expression of the mutant VPS35[D620N] in all tissues. 
We first investigated LRRK2 mediated Rab10 phosphorylation by immunoblot analysis in wild 
type, heterozygous and homozygous VPS35[D620N] primary mouse embryonic fibroblasts 
(MEFs) derived from E12.5 littermate embryos. This revealed that in two independent clones of 
homozygous VPS35[D620N] MEFs phosphorylation of Rab10 was strikingly elevated, around 
6-fold compared to wild type cells (Fig 2A). Significant 4 to 5-fold elevation of Rab10 
phosphorylation was also observed in heterozygous VPS35[D620N] MEFs. Treatment of MEFs 
with 100 nM MLi-2 LRRK2 inhibitor [35], reduced phosphorylation of Rab10 to nearly 
undetectable levels in wild type as well as VPS35[D620N] knock-in MEFs, confirming that 
Rab10 phosphorylation was mediated by LRRK2 (Fig 2A). Levels of LRRK2 and Rab10 as well 
as VPS35 and VPS26 were similar in heterozygous and homozygous VPS35[D620N] and wild 
type MEFs (Fig 2A), consistently with previous work showing that the VPS35[D620N] mutation 
does not impact on VPS35, and VPS26 expression levels [45-48]. Phosphorylation of LRRK2 at 
its Ser935 biomarker site [49], was also not significantly affected by the VPS35[D620N] 
mutation status (Fig 2A). 
 
VPS35[D620N] mutation enhances LRRK2 mediated phosphorylation of Rab8A and 
Rab12 in mouse embryonic fibroblasts 
To determine whether the VPS35[D620N] mutation enhances LRRK2 mediated phosphorylation 
of Rab proteins beyond Rab10, we exploited novel rabbit monoclonal antibodies, that permit 
LRRK2 mediated phosphorylation of Rab8A and Rab12 to be assessed. To monitor Rab8A 
phosphorylation, we immunoprecipitated Rab8A from extracts of wild type and homozygous 
VPS35[D620N] MEFs, employing a rabbit monoclonal antibody that we generated (MJF-22-74-
3), capable of quantitatively immunoprecipitating endogenous Rab8A from cell extracts (SFig 
1A, B). This antibody detects human and mouse Rab8A and its selectivity was confirmed using 
Rab8A knock-out cell line (SFig 1C). The Rab8A immunoprecipitates were immunoblotted with 
the previously described pRab8 antibody [20], revealing that Thr72 Rab8A phosphorylation is 
enhanced ~4-fold higher in VPS35[D620N] knock-in compared with wild type cells (Fig 2B). 
Treatment with MLi-2 LRRK2 inhibitor reduced Rab8A phosphorylation in wild type and 
VPS35[D620N] knock-in cells to background levels (Fig 2B). It is important that pRab8 
immunoblot analysis is undertaken in conjunction with immunoprecipitation of Rab8A, as the 
pRab8 antibody detects multiple LRRK2 phosphorylated Rab proteins [20].  
 
To assess LRRK2 phosphorylation of Rab12, we employed a new rabbit monoclonal antibody 
capable of detecting Rab12 phosphorylated at Ser106 in cell extracts (MJF-25-9-1). This 
antibody is strikingly selective and does not cross-react with any other LRRK2 phosphorylated 
Rab proteins (SFig 2A). We employed a CRISPR/CAS9 approach to generate Rab12 knock-out 
A549 cells, that express LRRK2, albeit at significantly lower levels than MEFs [20]. The MJFF-
pRAB12 monoclonal antibody detects phosphorylated Rab12 in wild type but not in Rab12 
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knock-out A549 cells, confirming specificity (SFig 2B). Moreover, MLi-2 treatment reduced 
phosphorylated Rab12 in wild type A549 cells consistent with LRRK2 mediating 
phosphorylation of this residue (SFig 2B). It should be noted that Rab12 is 4-5 kDa larger than 
other LRRK2 phosphorylated Rab proteins, and therefore endogenous LRRK2 phosphorylated 
Rab12 migrates with a notably higher molecular than Rab8 and Rab10. Direct immunoblotting of 
MEFs extracts with the pRab12 antibodies indicated that Rab12 phosphorylation was elevated, 
~4-fold in homozygous VPS35[D620N] knock-in cells compared to wild type cells (Fig 2B). 
Phosphorylation of Rab12 was reduced to basal levels in both wild type and homozygous 
VPS35[D620N] knock-in cells following MLi-2 inhibitor treatment (Fig 2B). Further 
immunoblot analysis of the same cell extracts, confirmed that LRRK2 mediated phosphorylation 
of Rab10 at Thr73 was also markedly increased in homozygous VPS35[D620N] knock-in cells 
(Fig 2B) 
 
Further evidence that elevated Rab10 phosphorylation in VPS35[D620N] knock-in MEFs is 
mediated by LRRK2 
To verify that elevated Rab10 phosphorylation in VPS35[D620N] knock-in cells was mediated 
by LRRK2, we employed siRNA to knock-down LRRK2 expression by ~80% in wild type and 
homozygous VPS35[D620N] knock-in MEFs (Fig 3A). This reduced LRRK2 mediated 
phosphorylation of Rab10 around 4-fold in wild type as well as homozygous VPS35[D620N] 
knock-in cells, compared to cells treated with control scrambled siRNA (Fig 3A).  
 
We also evaluated the ability of 3 structurally unrelated LRRK2 inhibitors namely MLi-2 [35], 
GSK2578215A [37] and PF-06447475 [38] to suppress elevated phosphorylation of Rab10 at 
Thr73 in VPS35[D620N] homozygous knock-in cells (SFig 3). All 3 inhibitors induced a dose 
dependent reduction of Rab10 phosphorylation that closely paralleled dephosphorylation of 
Ser935 on LRRK2, a widely used biomarker site for LRRK2 inactivation [49]. We estimated 
IC50 values for dephosphorylation of Rab10 by MLi-2 (<10 nM) [36], GSK2578215A (~100 
nM) [37] and PF-06447475 (10-30 nM) [38], that were within the range of previously reported 
values for Ser935 dephosphorylation. High doses of each of these inhibitors reduced Rab10 
phosphorylation to basal levels (SFig 3). 
 
VPS35[D620N] mutation enhances LRRK2 mediated autophosphorylation at Ser1292 in 
mouse embryonic fibroblasts 
Previous work has established that pathogenic mutations that activate LRRK2, including 
R1441G and G2019S, markedly elevate autophosphorylation of LRRK2 at Ser1292 [10, 50]. To 
explore whether the VPS35[D620N] mutation enhanced its autophosphorylation at Ser1292, we 
immunoprecipitated LRRK2 from wild type and VPS35[D620N] knock-in MEFs and subjected 
immunoprecipitates to phospho-immunoblot analysis. These experiments revealed that in both 
heterozygous as well as homozygous VPS35[D620N] knock-in MEFs, LRRK2 Ser1292 
phosphorylation was markedly elevated compared to wild type cells (Fig 3B). Consistently with 
Ser1292 phosphorylation mediated by LRRK2 autophosphorylation, 100 nM MLi-2 LRRK2 
inhibitor treatment, suppressed Ser1292 phosphorylation to basal levels (Fig 3B). These results 
are consistent with the VPS35[D620N] mutation promoting activation and hence 
autophosphorylation of LRRK2. 
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VPS35[D620N] mutation enhances LRRK2 kinase activity to a greater extent than LRRK2 
R1441C and G2019S pathogenic mutations  
We next undertook a side-by-side comparison of LRRK2 controlled Rab10 phosphorylation in 
homozygous knock-in VPS35[D620N] and previously described LRRK2[R1441C] [14] and 
LRRK2[G2019S] [20] knock-in MEFs (Fig 3C). For these studies the increased phosphorylation 
of Rab10 in knock-in cells was compared to that of littermate wild type cell lines generated in 
parallel to each of the knock-in cell lines (Fig 3C). These experiments revealed that the 
VPS35[D620N] mutation promoted Rab10 phosphorylation around ~ 6-fold, more than observed 
for the LRRK2[R1441C] (~4-fold) and the LRRK2[G2019S] (~2-fold) mutations (Fig 3C). 
Treatment with 100 nM MLi-2 LRRK2 inhibitor ablated Rab10 phosphorylation in all MEF 
lines. As a further control we also studied LRRK2 knock-out MEFs, which as expected exhibited 
no Rab10 phosphorylation. Expression of LRRK2, Rab10, and retromer components were 
similar in all wild type, knock-in as well as knock-out MEFs (Fig 3C). 
 
VPS35[D620N] mutation enhances LRRK2 mediated phosphorylation of Rab10 in mouse 
lung, kidney and spleen 
Consistent with a pervious report of a different strain of VPS35[D620N] knock-in mice 
generated using CRISPR/Cas9-mediated genome engineering [45], the homozygous Michael J. 
Fox Foundation VPS35[D620N] knock-in animals were born at the expected Mendelian 
frequency and displayed no overt phenotype at least up to 8 months of age which is the longest 
period that we have thus far maintained these mice. We analysed Rab10 phosphorylation in 
mouse tissues known to express high levels of LRRK2 (lung, kidney, spleen and brain) in 9-10 
weeks of age littermate wild type and VPS35[D620N] knock-in mice. For these experiments we 
studied six different animals of each genotype (Fig 4). This revealed that the homozygous 
VPS35[D620N] mutation robustly enhanced Rab10 phosphorylation around 3-fold in lung (Fig 
3A), kidney (Fig 4B) and spleen (Fig 4C), and 2-fold over background in brain (Fig 4D). 
Phosphorylation of Rab10 was reduced to basal levels following administration of 30 mg/kg 
MLi-2 inhibitor, demonstrating that this was mediated by LRRK2. Expression of LRRK2, 
Rab10, and retromer components were similar in all wild type and homozygous VPS35[D620N] 
knock-in tissues (Fig 4). 
 
Comparing LRRK2-mediated Rab10 phosphorylation in neutrophils from control, 
idiopathic and VPS35[D620N patients with PD 
To address the question of whether LRRK2 kinase activity is elevated in PD patients with 
VPS35[D620N] mutation, we assessed Rab10 phosphorylation in neutrophils derived from 
peripheral blood from three VPS35[D620N] PD patients using a recently described method [44]. 
In parallel, we also prepared neutrophils from nine age-matched patients with idiopathic PD 
carrying no known pathogenic mutation (Fig 5A) as well as nine non-age matched healthy 
controls (Fig 5B). Demographic and clinical data for each subject is presented in Supplementary 
Table 1. Prior to cell lysis, neutrophils were treated in the absence or presence of 200 nM MLi-2 
LRRK2 inhibitor for 30 min to ensure observed Rab10 phosphorylation was LRRK2 dependent. 
Quantitative immunoblot analysis revealed a striking ~3-fold elevation of Rab10 
phosphorylation in neutrophils derived from each of the three PD patients harbouring 
VPS35[D620N] compared to the average of all other patients with idiopathic disease (Fig 5A) or 
control samples (Fig 5B). Phosphorylation of Rab10 protein was higher in each of the three 
VPS35[D620N] patients’ neutrophils than observed in any of the other idiopathic or control 
 15 
samples (Fig 5). Rab10 total protein levels were remarkably constant between the different 
donors (Fig 5). MLi-2 treatment suppressed Rab10 phosphorylation to low background levels in 
all neutrophil samples confirming that Rab10 phosphorylation was mediated by LRRK2 (Fig 5). 
Levels of the retromer complex components VPS35 and VPS26 were also very similar in 
neutrophil samples isolated from control, VPS35[D620N] mutation and idiopathic subjects (Fig 
5). As observed in previous work suggesting that LRRK2 was significantly proteolysed in 
neutrophil extracts [44], immunoblot analysis revealed two species of LRRK2 migrating at 286 
kDa (full-length) and a more abundant 170 kDa species (Fig 5).  
 
Developing an assay to interrogate LRRK2 mediated Rab10 phosphorylation in human 
monocytes 
We next explored the feasibility of studying LRRK2 signalling in monocytes, as these are the 
only peripheral human blood cells other than neutrophils that express high levels of LRRK2 
(1 × 105 copies per cells) as well as Rab10 (2–4 × 106 copies per cells) [51]. Another potential 
advantage of monocytes over neutrophils is that they do not express high levels of elastase 
protease activity that leads to significant proteolysis of LRRK2. As a protocol to isolate 
monocytes for the assessment LRRK2 signalling had not been previously described, we first 
developed a method to isolate monocytes from peripheral blood exploiting an immune-magnetic 
negative isolation approach, in which all non-monocytic cells are targeted for removal with 
antibody complexes recognizing unwanted cells, including red blood cells, neutrophils and 
platelets, leaving only monocytes in the supernatant (see Materials and Methods). Flow 
cytometry analysis with the V500 Mouse Anti-Human CD14 monocyte marker revealed that the 
purity of monocytes isolated from each volunteer was 87-90% and viability of cells was 99% 
assessed with DAPI staining (Fig 6A and SFig 4). From 20 ml of blood, we obtained between 
0.06 to 0.11 mg of total protein from healthy donors, that is about 5 to 10-fold less than the 
amount of protein obtained from neutrophils isolated from the same donor (Fig 6A). This is 
expected as monocytes are much less abundant in human blood than neutrophils. Nevertheless, 
the amount of protein obtained from each monocyte preparation is sufficient for a handful of 
immunoblot analysis that typically require 10-20 µg protein per gel lane.  
 
To demonstrate feasibility of studying LRRK2 signalling in monocytes, we isolated monocytes, 
neutrophils and peripheral blood mononuclear cells (PBMCs) from the same 3 healthy volunteers 
(Fig 6 and SFig 4). Monocytes, neutrophils and PBMCs from each subject prior to cell lysis were 
treated in the presence or absence of 200 nM MLi-2 for 30 min. Quantitative immunoblot 
analysis revealed robust and similar levels of LRRK2 mediated phosphorylation of Rab10 were 
observed in monocytes as well as neutrophils, with lower levels seen in PBMCs (Fig 6C). In 
PBMCs LRRK2 expression is lower than observed in monocytes and neutrophils (Fig 6C). As 
was predicted, immunoblot analysis revealed significantly higher levels of full length LRRK2 in 
monocytes compared to neutrophils and PBMCs (Fig 6C). Ponceau S staining of immunoblots 
confirms a slight reduction of high molecular weight protein expression in neutrophils relative to 
monocytes and PBMCs likely due to enhanced proteolysis (Fig 6B). As predicted, full length 
LRRK2 was much more abundant in monocyte extracts compared to neutrophils (Fig 6). 
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Comparing LRRK2-mediated Rab10 phosphorylation in monocytes from control, 
idiopathic and VPS35[D620N] patients with PD 
We next isolated monocytes from the same three VPS35[D620N] patients as well as nine age-
matched idiopathic PD patients and nine non-age matched non-PD controls who provided 
neutrophils for the experiments shown in Figure 5. Monocytes from each subject prior to cell 
lysis were also treated in the presence or absence of 200 nM MLi-2 for 30 min. Quantitative 
immunoblot analysis of monocyte lysates, revealed a striking ~3-fold elevation of Rab10 
phosphorylation in the three VPS35[D620N] patients compared to idiopathic patients (Fig 7A) or 
controls (Fig 7B). MLi-2 treatment suppressed Rab10 phosphorylation to background levels in 
all monocyte samples confirming that Rab10 phosphorylation was mediated by LRRK2. Levels 
of total Rab10 protein and the retromer complex components VPS35 and VPS26 were very 
similar in monocytes derived from different donors (Fig 7).  
 
Knock-out and siRNA mediated knock-down of VPS35 suppress LRRK2 kinase activity 
To analyse the role of wild type VPS35 in regulating the activity of wild type LRRK2, we 
deployed a CRISPR/CAS9 genome editing approach to knock-out VPS35 in lung A549 cells that 
express significant levels of LRRK2. We analysed three independent VPS35 knock-out cell lines 
as well as three independent wild type cell lines that had all been single cell sorted and expanded 
in parallel. Strikingly, in all the VPS35 knock-out cell lines, levels of LRRK2 mediated Rab10 
phosphorylation were reduced 4 to 5-fold compared to wild type cells (Fig 8A & B). 
Consistently with previous work [52], knock-out of VPS35 led to a substantial reduction in 
VPS26, which is another core component of the retromer complex (Fig 8A).  
 
We also employed siRNA to knock-down VPS35 expression by ~80% in wild type (Fig 8C & 
D), VPS35[D620N] (Fig 8C) and LRRK2[R1441C] (Fig 8D) knock-in MEFs. This reduced 
LRRK2 mediated phosphorylation of Rab10 in wild type (~2-fold), VPS35[D620N] (~5-fold) 
and LRRK2[R1441C] (~2.5-fold), compared to cells treated with control scrambled siRNA (Fig 
8C & D). As expected, partial knock-down of VPS35 also lowered expression of VPS26 (Fig 8C 
& D). 
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Discussion 
Our data indicate that VPS35 lies upstream of LRRK2 and plays a role in regulating LRRK2 
kinase catalytic activity. This is based on the following findings: the pathogenic, PD causing 
VPS35[D620N] knock-in mutation stimulates LRRK2 mediated phosphorylation of at least 3 
Rab proteins (Rab8A, Rab10 and Rab12) in MEFs (Fig 2) as well as enhancing Rab10 
phosphorylation in mouse tissues that express LRRK2 (lung, kidney, spleen and brain) (Fig 4). 
In MEFs, we also demonstrate that the VPS35[D620N] knock-in mutation markedly enhances 
autophosphorylation of LRRK2 at Ser1292, consistent with LRRK2 becoming activated (Fig 
3B). Further evidence that the VPS35[D620N] mutation stimulates LRRK2 activity comes from 
data derived from human peripheral blood cells from 3 patients with VPS35 associated PD 
bearing the VPS35[D620N] mutation: Rab10 phosphorylation is markedly elevated in 
neutrophils (Fig 5) as well as monocytes (Fig 7) isolated from VPS35[D620N] PD patients in 
comparison to those from healthy donors or age-matched idiopathic PD patients. We also 
demonstrate that siRNA knock-down of LRRK2(Fig 3A) or treatment with MLi-2 (Fig 2-8) as 
well as two structurally unrelated LRRK2 inhibitors (PF-06447475, GSK2578215A) (SFig 3) 
markedly inhibit Rab10 phosphorylation in VPS35[D620N] knock-in cells. This provides strong 
evidence that elevated Rab10 phosphorylation induced by the VPS35[D620N] mutation is indeed 
mediated by LRRK2. 
 
While further studies involving greater numbers of VPS35[D620N] patients are needed to 
confirm that the VPS35[D620N] mutation stimulates Rab protein phosphorylation in humans, we 
are intrigued by the significant increase in Rab10 phosphorylation observed in peripheral blood 
cells from the three PD patients carrying the VPS35[D620N] mutation. In addition to studying 
further patients with VPS35 associated PD, it would be important to analyse phosphorylation of 
Rab10 as well as other Rab proteins in pre-symptomatic carriers of the VPS35[D620N] mutation. 
Further evidence supporting the notion that VPS35 lies upstream of LRRK2 comes from the 
finding that in CRISPR/CAS9 knock-out of VPS35 substantially reduces the activity of wild type 
LRRK2 in A549 cells (Fig 8A & B). Moreover, siRNA mediated knock-down of VPS35 
significantly reduced elevated LRRK2-mediated phosphorylation of Rab10 in LRRK2[R1441C] 
and VPS35[D620N] knock-in MEFs (Fig 8C & D).  
 
The finding that VPS35 lies in a common pathway with LRRK2 is consistent with previous work 
that is outlined in the introduction [32-34]. Taken together, these observations provide further 
evidence that a significant number of proteins encoded by genes mutated in genetic PD are likely 
to form part of common signalling networks. Perhaps the best characterised connection between 
two PD encoded proteins discovered to date, is between the PINK1 kinase and Parkin E3 ligase, 
where loss of function mutations cause autosomal recessive, young onset PD [53]. PINK1 
directly phosphorylates and activates Parkin E3 ligase activity in response to agents that induce 
mitochondrial depolarisation, which plays a vital role in regulating mitochondrial quality control 
in neurons [54, 55]. Another example for the crosstalk between signalling pathways in PD is the 
interaction between the protein encoded by RAB29 gene (located within the PARK16 locus) and 
LRRK2 [32, 56-58]. Recent work also reveals that Rab29 activates LRRK2 through an as yet 
unknown mechanism, by recruiting it to the trans Golgi network [10-12]. It will be critical to 
determine whether other monogenetic PD encoded proteins comprise upstream or downstream 
components of the LRRK2 signalling pathway. 
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We found that the heterozygous VPS35[D620N] mutation was sufficient to markedly activate 
LRRK2 mediated Rab10 phosphorylation 4-5-fold in MEFs, only slightly less than the 
homozygous mutation, that activated LRRK2 around 4 to 6-fold (Fig 2A). The heterozygous 
VPS35[D620N] mutation also enhanced Ser1292 autophosphorylation similarly to the 
homozygous mutation (Fig 3B). The finding that LRRK2 mediated Rab10 phosphorylation is 
significantly elevated in neutrophils (Fig 5) and monocytes (Fig 7) derived from patients with PD 
associated with a single copy of the VPS35[D620N] allele confirms that the heterozygous 
mutation is sufficient to potently activate LRRK2 kinase activity in humans. Our results support 
that the VPS35[D620N] mutation results in a gain of function that leads to the activation of the 
LRRK2 signalling pathway. Much previous work has also suggest that the VPS35[D620N] 
mutation acts in an autosomal dominant manner (Reviewed in [29]). 
 
Another potentially significant observation is that the homozygous VPS35[D620N] mutation 
activated LRRK2, based on assessing Rab10 phosphorylation, to a significantly greater extent (~ 
6-fold) than LRRK2[G2019S] (~2-fold) or LRRK2[R1441C] (~4-fold) (Fig 3C). If the degree of 
LRRK2 activation is relevant for pathogenesis of PD, a major prediction from our studies is that 
VPS35[D620N] carriers may develop PD at an earlier age than carriers with pathogenic LRRK2 
mutations, especially the G2019S mutation. This is currently difficult to assess rigorously due to 
the rarity of VPS35[D620N] associated PD. Most studies refer to VPS35[D620N] as “late 
onset”(reviewed [29]), while only one study comparing 35 unrelated PD cases of 
VPS35[D620N] concluded that the mean age at onset was 51.4 years (interquartile range, 45– 59 
years) [26]. Interestingly, analysis of the Movement Disorder Society (MDS) database [59], 
which contains 50 VPS35[D620N] patients, reveals that the largest group of patients, namely 23, 
were diagnosed with PD in the 5th decade, with only 13 diagnosed in the 6th decade (Fig 9A). In 
contrast, for LRRK2 G2019S carriers of the of which there are 277 in the MDS database, the 
largest groups of patients were diagnosed in 6th (73) and 7th decade (77) (Fig 9B). Additionally, 
the penetrance of the G2019S mutation is relatively low (as low as 24%) and most carriers may 
never develop disease [3, 60]. Consistent with a more pronounced effect on stimulating LRRK2 
kinase activity, the R1441G LRRK2 mutation appears to be more penetrant (up to 95% in later 
life) [3, 60]. We have pooled the low number of LRRK2 patients with known pathogenic hotspot 
mutations at Arg1441 in the ROC-COR GTPase domain listed in the MDS database (R1441C [n 
= 13], R1441S [n=6], R1441G [n=50], and R1441H [n =5], Fig 9C) [52]. For R1441H, we also 
included 3 additional patients published elsewhere [61, 62]. Additionally, the authors of a 
previously published paper that reported the mean age at onset and range of 49 patients 
withR1441G associated PD, kindly provided us with the age at onset for each individual [63]; 
data that we also included in Fig 9C. The age at onset of the LRRK2 ROC-COR mutation 
patients does appear to be similar to the G2019S, which lies in the kinase domain, but possibly 
slightly younger. Due to rarity of VPS35 associated PD, there is insufficient data to reliably 
estimate the penetrance of the VPS35[D620N] mutation. However, our prediction is that this 
would be more similar to LRRK2[R1441G] carriers than LRRK2[G2019S]. 
 
In future work it will be essential to decipher the mechanism by which VPS35 regulates LRRK2 
and how the VPS35[D620N] mutation enhances LRRK2 kinase activity. As the D620N mutation 
lies on the surface of VPS35, it is possible that it suppresses or potentiates the interaction of 
VPS35 with a specific interactor(s) that influences LRRK2 localisation and/or catalytic activity. 
It is also possible that VPS35 could directly interact with LRRK2. Indeed, one study reported 
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that in SHSY5Y cells as well as LRRK2 transgenic mouse brain, LRRK2 and the VPS35 subunit 
could be co-immunoprecipitated [32], although this was not observed in another study [34]. 
Several hundred proteins that co-immunoprecipitate with LRRK2 have been catalogued in a 
number of elegant proteomic studies, but to our knowledge the retromer complex components 
were not highlighted in these [56, 64]. Another report suggested that Rab29 also operates in a 
common pathway with VPS35 and LRRK2, which would be important to explore further [32]. 
The VPS35[D620N] mutant does not associate with the WASH complex as effectively as wild 
type VPS35, contributing to trafficking defects [48, 65]. In future work it would be essential to 
explore the role that the WASH complex as well as other retromer effectors plays in regulating 
the LRRK2 pathway. Above all, it would be critical to find out whether it is possible to identify 
specific protein(s) that interact differentially with the wild type and mutant form of LRRK2 and 
determine whether these proteins play a role in regulating LRRK2 activity and function (Fig 10). 
This work could lead to the uncovering of new regulators relevant to PD. 
 
From a clinical point of view, there is great interest in exploring the therapeutic benefit of 
LRRK2 inhibitors in PD [66]. One company (Denali Therapeutics) has initiated a Phase 1 
clinical trial with several others understood to be at a late-stage in preclinical assessment of 
diverse inhibitors [67]. Our work raises the possibility of elaborating inhibitors that target VPS35 
that could suppress the activation of LRRK2 (Fig 10). Identifying the molecular mechanism by 
which VPS35 activates LRRK2 will be critical, as this may provide new ways to suppress 
activation of LRRK2 kinase pathway. This could also lead to the discovery of new biomarker(s) 
that operate between VPS35 and LRRK2 that are relevant for assessing PD. This mechanistic 
analysis would ultimately provide a tractable framework to better understand underlying biology 
of the neurodegenerative process occurring in patients with genetic, but also idiopathic PD. For 
now, there is a rational that patients with VPS35[D620N] associated PD might benefit from 
future LRRK2 inhibitor treatment, in particular if the disease mechanism as well as the possibly 
earlier age of onset and possible higher penetrance of VPS35[D620N] PD is indeed driven by 
hyperactivation of the LRRK2 kinase pathway.  
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Figure Legends 
 
Figure 1. Location of the VPS35[D620N] mutation  
A) Ribbon (left panel) and Surface (right panel) of the previously described [31] complex of 
VPS29 (grey) and C-terminal domain of VPS35 subunit (red). The location of the Asp620 
residue that is mutated in Parkinson’s is shown in green. 
 
Figure 2. Heterozygous and homozygous VPS35[D620N] knock-in mutation in MEFs 
stimulates LRRK2 mediated Rab8A, Rab10 and Rab12 phosphorylation  
(A) Wildtype VPS35, VPS35[D620N/+], and homozygous VPS35[D620N/D620N] knockin 
MEFs derived from two independent sets of littermate embryos were treated ± 100 nM MLi-2 
inhibitor for 60 min prior to lysis. 10-20 µg of whole cell extract subjected to quantitative 
immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody 
concentration), and the membranes developed using the Odyssey CLx scan Western Blot 
imaging system (upper panel). Similar results were obtained in three separate experiments. 
Immunoblots were quantified by LiCor and presented as average ± SEM (lower panel). Each 
lane represents cell extract obtained from a different dish of cells. There was a statistically 
significant difference between groups for pT73Rab10/total Rab10 signal (P < 0.0001, oneway 
ANOVA, F(2, 6) = 508). Each lane represents cell extract obtained from a different dish of cells. 
(B) as in (A) except that 100 µg of whole cell extract was used for immunoprecipitation of 
Rab8A. The immunoprecipitates were subjected to Rab8-pT72 (90% of sample) and Rab8A-total 
immunoblot (10% of sample). Immunoblots were quantified by LI-COR and presented as 
average ± SEM (lower panel).  
 
Figure 3. Further evidence that the VPS35[D620N] mutation enhances LRRK2 kinase 
activity to a greater extent than LRRK2 R1441G and G2019S pathogenic mutations (A) 
Wildtype and VPS35 and homozygous VPS35[D620N/D620N] knockin MEFs were 
transfected with the indicated pool of three Dharmacon siRNAs targeting mouse LRRK2 or 
scrambled siRNAs as the control. 72 hours post transfection cells were lysed. 10-20 µg of whole 
cell extract subjected to quantitative immunoblot analysis with the indicated antibodies (all at 1 
µg/ml primary antibody concentration), and the membranes developed using the Odyssey CLx 
scan Western Blot imaging system and data presented as average ± SEM. Each lane represents 
cell extract obtained from a different dish of cells. VPS35 WT vs. VPS35 WT siLRRK2 P < 
0.005, oneway ANOVA, F(2, 2) = 18.5), VPS35 D620N vs. VPS35 D620N siLRRK2 
P<0.0001, oneway ANOVA, F(2, 2) = 18.5). (B) Wildtype VPS35, heterozygous 
VPS35[D620N/+], and homozygous VPS35[D620N/D620N] knockin were treated ± 100 nM 
MLi-2 inhibitor for 60 min prior to lysis. that endogenous LRRK2 was immunoprecipitated from 
2 mg of cell extracts and then subjected to immunoblot analysis with the indicated antibodies 
(upper panel). Due to lower sensitivity of the LRRK2 Ser1292 phospho-specific antibody, 
immunoblots were analysed using enhanced chemiluminescent detection quantified by 
autoradiography (P<0.0005 WT vs Het) (P<0.005 WT vs Hom). Each lane represents cell extract 
obtained from a different dish of cells. (C) The indicated matched wild type and homozygous 
knock-in or knock-out MEFs derived from littermate embryos (VPS35[D620N]-this study, 
R1441C [19]; G2019S-Eli-Lilly [13],  LRRK2 knock-out [41]) were cultured  lysed. 10-20 µg of 
whole cell extract was subjected to quantitative immunoblot analysis with the indicated 
antibodies (all at 1 µg/ml primary antibody concentration), and the membranes developed using 
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the Odyssey CLx scan Western Blot imaging system (upper panel). Each lane represents cell 
extract obtained from a different dish of cells. Similar results were obtained in two separate 
experiments. Blots were signals quantified by LiCor and presented as average ± SEM (lower 
panel). There was a statistically significant difference between groups for pT73Rab10/total 
Rab10 signal P < 0.0001, oneway ANOVA, F(3, 8) = 460.5)  
 
Figure 4. VPS35[D620N] mutation enhances LRRK2 mediated phosphorylation of Rab10 
in mouse lung, kidney and spleen 
(A to D) Wildtype VPS35 and homozygous VPS35[D620N/D620N] knockin littermate mice of 
9-10 weeks of age were administered with MLi-2 (30 mg/kg) by subcutaneous injection. After 
60 min, animals were killed, and the lung (A), kidney (B), spleen (C) and brain (D) extracts were 
generated and immunoblotted with the indicated antibodies. 10-40 µg of whole cell extract were 
subjected to quantitative immunoblot analysis with the indicated antibodies (all at 1 µg/ml 
primary antibody concentration), and the membranes developed using the Odyssey CLx scan 
Western Blot imaging system (upper panels). Each lane represents tissues obtained from a 
different animal. Similar results were obtained in two separate experiments. Blots were signals 
quantified by LiCor and presented as average ± SEM (lower panels). There was a statistically 
significant difference between groups for pT73Rab10/total Rab10 signal, Mouse Lung P < 
0.005, oneway ANOVA, F(5, 5) = 8.2), Mouse kidneys P<0.0001 oneway ANOVA, F(5, 5) = 
4.5), Mouse Spleen P<0.005 oneway ANOVA, F(5, 5) = 4.99), Mouse Brain P<0.05 oneway 
ANOVA, F(5, 5) = 1.18) 
 
Figure 5. Comparing LRRK2-mediated Rab10 phosphorylation in neutrophils from 
control, idiopathic and VPS35[D620N] Parkinson's patients. 
Neutrophils were isolated from 9 age matched idiopathic Parkinson's disease patients, nine non-
age matched healthy controls, and 3 individuals with a heterozygous VPS35[D620N] mutation 
with Parkinson's disease. Demographic and clinical data for each subject analysed is provided in 
Supplementary Table 1. Cells were treated with or without 200 nM MLi-2 for 30 min. 
Neutrophils were then lysed and 10 µg of whole cell extract subjected to quantitative 
immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody 
concentration), and the membranes developed using the Odyssey CLx scan Western Blot 
imaging system. (A) Samples from 9 age matched idiopathic Parkinson's disease patients 
controls and 3 individuals with a heterozygous VPS35[D620N] mutation with Parkinson's 
disease were analysed (left and middle panel) by immunoblotting analysis with the indicated 
antibodies. Samples analysed on the left hand and middle panels were generated about 8 weeks 
apart and analysed on different gels. The same internal standard was run on every gel in order to 
compare the different sets of samples. Similar results were obtained in two independent 
immunoblot experiments of the same extracts. Immunoblots from were quantified for phospho-
Thr73 Rab10/total Rab10 ratio (right panel). Data were analysed by one-way ANOVA with 
Tukey's multiple comparison test. Data presented as means ± SD; *** p<0.0001. (B) As in (A) 
except neutrophil extracts from 9 non-age-matched control samples were compared with the 
same 3 individuals analysed in (A) with a heterozygous VPS35[D620N] mutation with 
Parkinson's disease. 
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Figure 6. Developing an assay to interrogate LRRK2 mediated Rab10 phosphorylation in 
human monocytes 
Monocytes, neutrophils and PBMCs were isolated from whole blood of the same 3 healthy 
donors (termed A, B & C) in parallel and treated with or without 200 nM MLi-2 for 30 min. (A) 
After gating around cells, the viability (DAPI) and purity of monocytes (CD14-positive) and 
Neutrophils (CD66b-positive) was assessed via flow cytometer analysis. Flow cytometry was 
also used to assess viability and the proportion of B cells (CD19-positive), monocytes (CD14-
positive), T cells (CD3-positive) and contaminating neutrophils (CD66b-positive) in each of the 
3 PBMC preparations (Supplementary Figure 4). (B & C) Monocytes, neutrophils and PBMCs 
were then lysed and 10 µg of whole cell extract subjected to SDS-PAGE and western blotting 
and the resulting membranes were stained with Ponceau S solution (B) or subjected to 
quantitative immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody 
concentration) and the membranes were developed using the Odyssey CLx scan Western Blot 
imaging system (C).  
 
 
Figure 7. Comparing LRRK2-mediated Rab10 phosphorylation in monocytes from control, 
idiopathic and VPS35[D620N] Parkinson's patients 
Monocytes were isolated from 9 age matched idiopathic Parkinson's disease patients, nine non-
age matched healthy controls, and 3 individuals with a heterozygous VPS35[D620N] mutation 
with Parkinson's disease. Demographic and clinical data for each subject analysed is provided in 
Supplementary Table 1. Cells were treated with or without 200 nM MLi-2 for 30 min. 
Monocytes were then lysed and 10 µg of whole cell extract subjected to quantitative immunoblot 
analysis with the indicated antibodies (all at 1 µg/ml primary antibody concentration), and the 
membranes developed using the Odyssey CLx scan Western Blot imaging system. (A) Samples 
from 9 age matched idiopathic Parkinson's disease patients controls and 3 individuals with a 
heterozygous VPS35[D620N] mutation with Parkinson's disease were analysed (left and middle 
panel) by immunoblotting analysis with the indicated antibodies. Samples analysed on the left 
hand and middle panels were generated about 8 weeks apart and analysed on different gels with 
immunoblotting undertaken in parallel. The same internal standard was run on every gel in order 
to compare samples run on different gels. Similar results were obtained in two independent 
immunoblot experiments of the same extracts. Immunoblots from were quantified for phospho-
Thr73 Rab10/total Rab10 ratio (right panel). Data were analysed by one-way ANOVA with 
Tukey's multiple comparison test. Data presented as means ± SD; *** p<0.0001. (B) As in (A) 
except monocyte extracts from 9 non-age-matched control samples were compared with the 
same 3 individuals analysed in (A) with a heterozygous VPS35[D620N] mutation with 
Parkinson's disease. 
 
Figure 8: Knock-out and siRNA mediated knock-down of VPS35 suppress LRRK2 kinase 
activity 
(A) Three independent wildtype (WT1, WT2 and WT3) VPS35 and three independent 
CRISPR/CAS9 VPS35 knock-out (KO1, KO2 and KO-3) A549 cells that had all been through 
the identical single cell sorting and expansion procedure were treated ± 100 nM MLi-2 inhibitor 
for 60 min prior to lysis. 10 µg of whole cell extract subjected to quantitative immunoblot 
analysis with the indicated antibodies (all at 1 µg/ml primary antibody concentration), and the 
membranes developed using the Odyssey CLx scan Western Blot imaging system. Similar 
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results were obtained in three separate experiments. (B) Immunoblots were quantified by LiCor 
and presented as average ± SEM. There was a statistically significant difference between groups 
for pT73Rab10/total Rab10 signal P < 0.0001, oneway ANOVA, F(3, 20) = 361). (C) Wild
type and VPS35 and homozygous VPS35[D620N/D620N] knockin MEFs were transfected with 
the indicated pool of three Dharmacon siRNAs targeting mouse VPS35 or scrambled siRNAs as 
the control. 72 hours post transfection cells were lysed and immunoblotted with the indicated 
antibodies (upper panel). Similar results were obtained in three separate experiments. 
Immunoblots were quantified by LiCor and presented as average ± SEM. VPS35 WT vs. VPS35 
WT siVPS35 P < 0.0001, oneway ANOVA, F(2, 2) = 7.8), VPS35 D620N vs. VPS35 D620N 
siVPS35 P<0.0001, oneway ANOVA, F(2, 2) = 7.3). (D) As in (C) except that Wildtype 
LRRK2 and homozygous LRRK2 [R1441C/ R1441C] knockin MEFs were used. LRRK2 WT 
vs. LRRK2 WT siVPS35 P<0.005, oneway ANOVA, F (2, 2) = 3.4), LRRK2 R1441C vs. 
LRRK2 R1441C siVPS35 P<0.05, oneway ANOVA, F(2, 2) = 281) 
 
Figure 9: The age of onset of Parkinson’s in patients with pathogenic VPS35[D620N], 
LRRK2[G2019S] and LRRK2[ROC-COR] mutations using data available from the MDS  
database 
The age at onset (AAO) of PD patients with pathogenic mutations in (A) VPS35[D620N] 
(n=50), (B) LRRK2[G2019S] (n = 277), and (C) LRRK2[ROC-COR mutations encompassing 
R1441C [n = 13], R1441S [n=6], R1441G [n=50], and R1441H [n =5] as listed in the MDS gene 
database (http://www.mdsgene.org/) [58]. For R1441H, we included 3 additional patients 
published elsewhere and not included in the MDS gene database (1 patient each with AAO 32 
and 57 [60] as well as 1 with AAO 59 [61]). For R1441G, we also included 49 additional cases 
not listed in the MDS gene database and whose AAO had previously been reported as a mean 
61.7±8.5 years; range 44–80 years [63]. The authors of the later study kindly made the 
information for the individual AAO available to us. 
 
Figure 10: Schematic summary showing how VPS35 might regulate LRRK2 and LRRK2 
protein kinase activity and hence Parkinson’s Disease. The mechanism by which LRRK2 is 
activated in vivo has not been elucidated. It is also not known what maximal activation of 
LRRK2 kinase activity is achievable. It is thought that the LRRK2 pathogenic mutations cause 
only a partial activation of LRRK2. Mutations in the kinase domain, such as G2019S, induce a 
moderate ~2-fold activation of LRRK2, perhaps by stabilizing the active confirmation of the 
kinase fold. Pathogenic mutation in the ROC/COR domain of LRRK2, such as R1441G/C, 
increase LRRK2 kinase activity around 3 to 4-fold. Three recent papers [10-12] indicate that the 
ROC/COR mutations, promote recruitment of LRRK2 to the Rab29 protein that is located at the 
Golgi, which leads LRRK2 activation through an as yet unknown mechanism.  VPS35 and 
Rab29 could operate in the same pathway with LRRK2 [32] . Our work shows that the 
VPS35[D620N] mutation through an unknown pathway is inducing a higher 5 to 6-fold 
activation of LRRK2 than achieved with the known pathogenic mutations. Indeed this is 
supported by age-of -onset data shown in Figure 9 that suggest that Parkinson’s patients with 
VPS35[D620N] develop the disease at a younger age than those with LRRK2 mutations.  In 
future work it would therefore be vital to define the mechanism by which VPS35[D620N] is 
activating LRRK2 and explain why VPS35[D620N] mutations induce a greater activation of 
LRRK2 than observed with the LRRK2 pathogenic mutants. We propose that by understanding 
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this mechanism it might be possible to develop compounds that target the retromer complex that 
suppress activation of LRRK2 
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Supplementary Tables S1: Demographic and clinical data for participants analysed in 
Figures 4 and 6  
 
Supplementary Figure 1. Characterisation of the rabbit monoclonal Rab8A-total (MJF-22-
74-3) antibody. (A & B) Wildtype MEFs treated ± 100 nM MLi-2 inhibitor for 60 min prior to 
cell lysis. For immunoprecipitation analysis 100 µg of whole cell extract was subjected to 
immunoprecipitation employing either the Rab8A-total (MJF-22-74-3) antibody or Pre-immune 
IgG (used as a control). The immunoprecipitates were subjected to Rab8A-total (10% of sample) 
and Rab8-pT72 immunoblot (90% of sample) (all at 1 µg/ml primary antibody concentration). 10 
µg of whole cell extract or supernatants after immunoprecipitation were subjected to Rab8A-
total immunoblot. (C) The indicated lysates of A549 wild-type and A549 Rab8A knock-out cells 
(10 µg), HEK293 cells (10 µg), human PBMCs (5 µg), wild-type MEFs (10 µg), as well as 
mouse lung, spleen, kidney and brain lysates (20 µg) were subjected to Rab8A-total (MJF-22-74-
3) immunoblot analysis.  
 
Supplementary Figure 2. Characterisation of the rabbit monoclonal Rab12-pS106 (MJF-
25-9-1) antibody. (A) HEK293 cells were co-transfected with plasmids encoding the 
LRRK2[Y1699C] pathogenic mutation and the indicated Rab protein that all possessed an N-
terminal HA tag. 36 hours post transfection, cells were treated ± 150 nM MLi-2 inhibitor for 90 
min prior to cell lysis. 0.5 µg of whole cell extract was subjected to quantitative immunoblot 
analysis with the indicated antibodies (all at 1 µg/ml primary antibody concentration), and the 
membranes developed using the Odyssey CLx scan Western Blot imaging system. (B) The 
indicated wild type and Rab12 knock-out A549 cells were treated ± 100 nM MLi-2 for 90 min 
prior to cell lysis. Generation of the Rab12 knock-out cells is described in the materials and 
methods. 30 µg of whole cell extract was subjected to quantitative immunoblot analysis with the 
indicated antibodies (all at 1 µg/ml primary antibody concentration). The membranes developed 
using the Odyssey CLx scan Western Blot imaging system. A duplicate Rab12-pS106 
immunoblot analysis was developed using enhanced chemiluminescence (ECL) for comparison.  
 
Supplementary Figure 3: Three structurally unrelated LRRK2 inhibitors reduce elevated 
Rab10 phosphorylation in dose dependent manner in homozygous VPS35[D260N] knock-in 
cells. Homozygous VPS35[D620N] knock-in and wild-type MEFs were treated with the 
indicated doses of MLi-2 [34, 35], GSK2578215A [36] and PF-06447475 [37] LRRK2 inhibitor 
for 60 min prior to cell lysis. 7.5 µg of whole cell extracts were subjected to quantitative 
immunoblot analysis with the indicated antibodies (all at 1 µg/ml primary antibody 
concentration), and the membranes developed using the Odyssey CLx scan Western Blot 
imaging system. Immunoblots were quantified by LiCor and presented as average ± SEMπ. Each 
lane represents cell extract obtained from a different dish of cells. 
 
Supplementary Figure 4: Flow cytometry analysis to determine the purity and viability of 
isolated monocytes and neutrophils, and the composition of PBMC.  
Purified monocytes were stained with the monocyte specific marker CD14 employing anti-
human CD14 V500 antibody while purified neutrophils were stained with the granulocyte 
specific marker CD66b using anti-human CD66b FITC antibody. Cells were also stained with 
the cell viability dye DAPI. Cells were analysed by flow cytometry revealing that isolated 
monocytes had a viability >99% and a purity 87-90%, while isolated neutrophils had a viability 
 34 
>99% and a purity 94-98%. PBMC were stained with the B cell marker CD19 APC, the T cell 
marker CD3 PE, the monocyte marker CD14 V500, the granulocyte marker CD66b FITC and 
DAPI. * corresponds to the monocyte and granulocyte parent gate. The proportion of each cell 
type within the isolated PBMC is provided. The data shown is for Donor A. A summary of the 
viability and purity data for all three donors is provided in Figure 6A. 
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Table 1. AnƟgens employed for rabbit monoclonal Rab anƟbodies generaƟon 
ANTIBODY ABCAM 
project 
number 
ANTIGEN NAME OF 
MONOCLONAL 
ANTIBODY 
Rab8A total MJF-22 
Full-length protein: 
MAKTYDYLFKLLLIGDSGVGKTCVLFRFSEDAFNSTFISTIGID
FKIRTIELDGKRIKLQIWDTAGQERFRTITTAYYRGAMGIML
VYDITNEKSFDNIRNWIRNIEEHASADVEKMILGNKCDVND
KRQVSKERGEKLALDYGIKFMETSAKANINVENAFFTLARDI
KAKMDKKLEGNSPQGSNQGVKITPDQQKRSSFFRCVLL 
PepƟde: 
C-KMDKKLEGNSPQGSNQGVKITPDQQKRSSFFR 
MJF-22-74-3 
Rab12 
pSer106 
MJF-25 
C-Ahx-AGQERFNS*ITSAYYR-amide 
Ac-AGQERFNS*ITSAYYR-Ahx-C 
MJF-25-9-1 
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Supplementary Table S1: Demographic and clinical data for subjects analysed in 
Figures 4 and 6. Abbreviations iPD idiopathic Parkinson’s disease; N/A not applicable; 
Age at Onset of Parkinson’s disease AAO 
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